drug-discovery
MSD joins the Open Targets consortium
AI annotations increase patent data in SureCheMBL
Understanding the mechanisms of enzyme catalysis
Welcome: David Hulcoop
David Hulcoop appointed as Open Targets Director
ProtVar: understanding missense variation in humans
Bioinformatics powers international effort to map gene function
A human interactome to prioritise drug discovery
Machine learning to identify and prioritise drug targets
Pfizer joins the Open Targets consortium
AI for drug discovery: what’s the hold up?
The PROTACtable genome – a new route to drug discovery
Repurposing drugs to manage COVID-19 progression
Data integration to speed up drug discovery
Using drug screens and CRISPR to make better cancer drugs
eQTL Catalogue – a new resource for gene expression and splicing QTLs
CRISPR offers new insights into critical cancer changes
Ian Dunham appointed as Open Targets Director
Sanofi joins Open Targets
Classification of pre-clinical data could boost drug research
Celgene joins Open Targets
Takeda joins drug target discovery initiative
A better way to find drug targets
Open Targets: new name, new data
Biogen Joins Pioneering Target Validation Collaboration
Target Validation Platform launches
ChEMBL_19 Released - Now with Crop Protection Data!
Where do you start when developing a new medicine?
The Pistoia Alliance and EMBL-EBI announce HELM collaboration for cheminformatics
BLAST off! Exploring the universe of biochemical reactions
